Trial · NCT01887600
Results by group510
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 510
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response | Roxadustat | 79.2 | 95% Confidence Interval 74.8 to 83.1 | Percentage of Participants | |
| Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response | Placebo | 9.9 | 95% Confidence Interval 6.1 to 14.8 | Percentage of Participants | |
| Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy | Roxadustat | 1.992 | 95% Confidence Interval 1.82 to 2.16 | g/dL | |
| Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue Therapy | Placebo | 0.300 | 95% Confidence Interval 0.09 to 0.51 | g/dL | |
| Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period | Roxadustat | 2.069 | 95% Confidence Interval 1.94 to 2.20 | g/dL | |
| Hb Change From BL to the Average Hb in Weeks 28-36 Without Having Received Rescue Therapy Within 6 Weeks Prior to and During 8-Week Evaluation Period | Placebo | 0.470 | 95% Confidence Interval 0.30 to 0.64 | g/dL | |
| Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28 | Roxadustat | -0.650 | 95% Confidence Interval -0.76 to -0.54 | mmol/L | |
| Change From BL in Low-Density Lipoprotein (LDL) Cholesterol (Regardless of Fasting Status) to the Average LDL Cholesterol of Weeks 12 to 28 | Placebo | 0.051 | 95% Confidence Interval -0.08 to 0.18 | mmol/L | |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Roxadustat | Year 0.5 | 6.1 | 95% Confidence Interval 3.6 to 8.7 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Placebo | Year 0.5 | 33.3 | 95% Confidence Interval 26.5 to 40.1 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Roxadustat | Year 1 | 13.0 | 95% Confidence Interval 9.3 to 16.7 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Placebo | Year 1 | 50.1 | 95% Confidence Interval 42.4 to 57.7 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Roxadustat | Year 1.5 | 22.0 | 95% Confidence Interval 16.6 to 27.3 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Placebo | Year 1.5 | 52.5 | 95% Confidence Interval 44.5 to 60.5 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Roxadustat | Year 2 | 26.3 | 95% Confidence Interval 20.2 to 32.4 | Percentage of participants |
| Time to First Use of Rescue Therapy (Composite of Red Blood Cell (RBC) Transfusions, Erythropoiesis-stimulating Agent (ESA) Use, and Intravenous (IV) Iron) | Placebo | Year 2 | 57.8 | 95% Confidence Interval 48.7 to 66.9 | Percentage of participants |
| Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28 | Roxadustat | 2.788 | 95% Confidence Interval 1.56 to 4.01 | Units on a Scale | |
| Change From BL in Short Form (SF)-36 Vitality (VT) Sub-score to the Average VT Sub-score of Weeks 12 to 28 | Placebo | 1.661 | 95% Confidence Interval 0.23 to 3.10 | Units on a Scale | |
| Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28 | Roxadustat | 1.344 | 95% Confidence Interval 0.15 to 2.54 | Units on a Scale | |
| Change From BL in SF-36 Physical Functioning (PF) Sub-score to the Average PF Sub-score of Weeks 12 to 28 | Placebo | 0.632 | 95% Confidence Interval -0.76 to 2.03 | Units on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01887600/results